Bioxytran Inc Stock OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Bioxytran, Inc. Announces Board Changes | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 21.85M 30.08M |
---|---|---|---|---|---|
Net income 2022 | -2M -2.75M | Net income 2023 | -4M -5.51M | EV / Sales 2022 | - |
Net Debt 2022 | 1.87M 2.57M | Net Debt 2023 | 1.9M 2.61M | EV / Sales 2023 | - |
P/E ratio 2022 |
-22.4
x | P/E ratio 2023 |
-4.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.12% |
Managers | Title | Age | Since |
---|---|---|---|
David Platt
CEO | Chief Executive Officer | 71 | 18-02-28 |
Ola Soderquist
DFI | Director of Finance/CFO | 63 | - |
Leslie Ajayi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Platt
CEO | Chief Executive Officer | 71 | 18-02-28 |
Dale Conaway
BRD | Director/Board Member | 69 | 18-11-01 |
Anders Utter
BRD | Director/Board Member | 57 | 18-11-01 |
1st Jan change | Capi. | |
---|---|---|
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.47% | 16.37B | |
+2.23% | 13.58B | |
+27.13% | 11.66B |